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A periodic, hard-lheaded assessment of technology has become a routine and
plrofitable exercise for most of the large industrial enterprises of the nation. Otur
methiods for securing energy, for example, whethier from fossil fuels or atoms or
straighlt from the stLin, are subjected to regular review by panels of experts, in and
otut of government, in order to make forecasts for the future and arrive at pru-
(lenit decisions about long-range budgets. Technology assessment is an essential
feature of ouir progress in space, defense, transport, agriculture and environ-
mental protection.
The blroad field of medicine lhas, tup to now, received very little of this kind
of treatment. We lhave tended to accept the technology of medicine as a given,
as sometlhing that is simply there, for better or worse, to be taken for granted.
Wlhen we have used the term technology it has in fact usually been in the sense-
a very limited sense, in my view-of the technology involved in the actual de-
livery of health services.
It might be useful for all of us, in and out of medicine, to take a careful look
at all the actual measures employed in the management of (lisease and the preser-
vation of health, and to make, periodically, the same objective appraisals of their
effectiveness as are ma(le by other national enterprises based on science. It would
be a lot easier to work out long-range policies and set future goals if we had
some system in operation to tell us, at any given moment, where we stand in our
capacity to (leal with specific, major diseases of man, what these measures are
costing us, and whether there are any options in sight, i.e., whether there is new
'Ihis paper was presented, in part, as testimony in hearings of the United States Setiate
Appropriations Committee on National Priorities, in February, 1972. The cornplete testimony is
to be published in Federation Proceedings.
111
Copyright ©l 1972, by Academic Press, Inc.THOMAS
information to indicate that basic changes in technological approaches may be
just ahead.
Having said this, I must confess that I'm not sure that it can be done. It would
be a formidable task, involving large numbers of people with all kinds of exper-
tise in lhealtlh matters. AMoreover, the task would be much complicated by the
fact that there is a major, crucial (lifference between the healtlh enterprise, viewved
as an i(ldustry, and all thie otlher fiel(ds of science and teclhnology. The difference
is this: In every other endleavor, measures that prove to be only marginally effec-
tive, or almost effective, can be discarded out of hand. If there is a process for
energy production which (lerives from a brilliant new i(lea, and works wonder-
fully, but costs too muclh money, it is set to one sicle or reserved for further re-
searclh. WVe do not build expensive bridges unless it can be proven that the ex-
pected traffic will be heavy enough to bear the cost. Cost and effectiveness are
cointinually being weiglhed against each other. This is not the case in medicine.
It is our history that if somethliing turns tup that will affect for tlle better a very
small percentage of patients with an otherwise untreatal)le (lisease, we are obliged,
by the very nature of our professional responsibility, to adopt that technology
and use it for all it is wortlh, without counting the cost. If we can do somethiilg
to save the life of one patient out of a hiundred, we must do it, and moreover, we
must make it available to all hundred even tlhouglh 99 will not be lhelped. We
cannot use cost-effectiveness in the way that other indlustries use it for guidance.
If something works for us, in terms of saving lives or stopping pain or disability,
we are compelled to use it, an(d society expects us to behave in this way. XVe can-
not withllold a technology from the marketplace because it costs too muclh money
or benefits too small a percentage of patients.
The best we can do when the economic or logistic problems associated with
our technology verge on the insupportable, or when the oddls are too higlh against
the success of our procedures, is to try to improve the teclhnology, or to discover
an altogether new technology, as quickly as possible. AMeanwhile, however, we
must continue to employ the less than satisfactory ones.
Typhoid fever providles a good example from relatively recent history of this
kindl of dilemma. For a long time we had no idea about the cause of this disease,
and all our efforts were (lirected against the symptoms. Thus, we developed a
marginally effective sort of teclhnology for the control of fever, and learned how
to intervene surgically for the perforations and hemorrlhages in the intestinal tract
wlhiclh were the great hazards of (leatlh in this (lisease. Wlhen thle typhoid bacillus
was discovered to b)e the cause we gradually (levise(l a pullic lhealth teclh-
nology to control the spread of the disease. Finally, two decades ago, chloram-
pIhenicol was discovered, and it became possible to cure typhoid fever outright
whenever it occurred. Today, typhoid no longer represents a serious or difficult
problem for medicine in this country, nor is it any longer a significant economic
problem. Chloramplhenicol, whiclh represents the "high technology" of typlhoid
fever, has clhanged it from a (lisease lasting six to ten weeks, witlh a substantial
mortality, which certainly would cost an average patient at least $10,000 in a
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moclern American lhospital, to a minor problem curable in a few hours, and for
a few cents.
All of us wish this is the way it would go for all the rest of human disease, and
the optimists among us, including myself, are convinced that eventually it will
go this way. But we are still a long way off. The near-miraculous achievements
of the antibiotic drtugs in controlling or eliminating our most serious bacterial
infections such as typlhoid or lobar pneumonia, or epidemic meningitis- are
usefuil indicators of the future direction of technology in medicine. They are, in
fact, pieces of solid evidence that technology does work. Bult they should not be
mistaken for symbols of the whole of medicine. WVe have nothing at all like this
technology yet for cancer, for heart (lisease, or stroke, or for a great number of
other extremely important human diseases. WVe are still lacking the essential
basic iniformation about the mechanisms of these diseases on which to build an
effective technology.
For some, we seem to be part way along. Diabetes is a good example. There
was a time, in the 1920's, when it appeared that insulin had solved the problem.
The great hazard of that (lay was acute coma, andI (leath from diabetic acidosis,
and insuilini is unquestionably the cure for that. However, it soon became clear
that dliabetes remains, despite insulin, as a chronic, progressive and often fatal
disease, in whliclh the 1)lood vessels of the kidneys, heart and brain are the princi-
pal targets, and we still lack an understanding of how this part of the (lisease
works. We are tlherefore unable to prevent or reverse the vascular disease.
The technology of medicine is a mixture of things, some marvelously effective,
some partially effective, some only palliative. To get a somewhat clearer view of
where we stand, I have proposedI the following rough classification, based on
three quiite clifferent levels of technology(l). I shoul(d emphasize, at the outset,
that our methocls of managing disease are constantly changing, as new items of
information are brouglht in from the various biomedical sciences, so the position
of different (liseases in this kind of classification is subject to change at any time.
The three levels, however, remain fixed and useful categories for assessment:
1. Non0-technological Medical Care. The first level is the large body of what is
best terme(d "'non-teclhnology," since it does not involve measures directed at the
underlying mechanisms of disease, nor can it be shown to alter, predictably,
either the natural course or eventual outcome of (lisease. It is, in effect, the sur-
rogate for technology which medicine has traditionally been compelled to use
for diseases that are not understood. A great deal of money is spent on this, and
it is higlhly regarded by the professionals as well as patients. It consists of what
is sometimes called "supportive therapy," "caring for," or simply "standing by."
In part, it consists of reassurance, since much of a physician's time is spent in
explaining to patients in fear of one disease or another that they are, in fact, well.
It is wlhat the doctor was once required to do, not very long ago, at the bedside
of patients with diphtheria, meningitis, poliomyelitis, lobar pneumonia, scarlet
fever, and all the rest of the infectious diseases that have since come under con-
trol. And now, it is what he must do for patients with intractable cancer, severe
rheumatoid arthritis, multiple sclerosis, stroke, advanced cirrhosis, and several
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varieties of mental (lisease. One coul(l list a score of major lhulman diseases for-
wliiclh this is the only available kind of management.
The cost of non-teclhnology is hiiglh, and getting higher all the time. It takes
time, (levotion ancl constummiiate skill on the part of physicians; only the very
best of (loctors are goodl at coping witlh this kin(d of (lefeat. It involves lhospitaliza-
tion, nutrsing care, andl non-pr-ofessional lhealtlh workers at all levels. It represents
a very sulbstantial part of toclay's expenditutres for healtlh care.
2. Halfwiiay Techniology. At the next level uip is a kind of teclhnology (lesigned
I)rimarily to compensate for the destructive effects of certain diseases wlhose
coturse we are unable to affect; it attempts to make uip for (lisease, or to postpone
(leatlh. Thlie most spectaculahr examples in recenit years are the transplantations of
vital organs, and the efforts to invent artificial organs. The ptlblic tends to view
these as poteintial triumphs, breakthroughs, insteadl of the makeshift stopgaps
that they really are. The wlhole array of complex teclhlnological measures for
coronary lheart dlisease, rangying from anticoagutlants tlhroughl coronary care uinits
to theultimlate feat of replacement of thelheart, represent tlle kindcls of tllings we
are o1)liowed to do in the face of a (lisease whlose dlrivinu meclhaniism remains a
lpizzle.AVWhen the ptuzzle is solved, mtuclh if not all of today's proliferating teclh-
nology can be set to one si(le.
WVeusedl to be involveJ in a complicatedlhalfway technology, at a more primi-
tive level, in our management of infectious diseases. The making of a ttlrpentine
sttupe was once a central part of the management of typhoi(, and( no simple mat-
ter. Poliomyelitis, less than two decades ago, was aprolblem forphysiotherapists
and orthopedic surgeons. Ttuberculosis, prior to the introdutiction of streptomycin andl INH, was beginning to involve an expanding teclhinology of thoracic sturgery.
It is characteristic ofhalfway teclhnologies that tlhey cost great amounts of
money and deman(d a cointinuiiing expansion ofhospital facilities. There is no
endl to the need for new,higlhly trainecl people torutni the enterprise. And, so
far as I can see, there is no wvay out of tlhis, at our present stage of knowvle(dge.
The installation of specialized coronary care uinits will prol)albly extend tlle lives
of a fewpatients witlh coronlary thirombosis, but even if only a very few can be
saved it seems inevital)le that we will btuild as many suclh uinits aswe can, regard-
less of cost. The onily imaginable source of new information that can moveus
away from this level of teclhnology is research.
3. High Techniology. The third kind is the decisive, conclusive technology of
miodlern medicine, (lesigne(l toprevent or reverse the primary mechanismns of (lis-
case, exemplified by today's methods for immunization against variotus infectiolls,
aind today'suse of antibiotics and chemotlherapy for bacterial (lisease. The capa-
city to deal effectively witlh tuberculosis and syphilis is a milestone in huiman
endeavor, even thotgih ftull tise of this potentiallhas not yet been madle. There
are, of course, other examples: the specific prevention of letlhal or incapacitating
nutritional diseases, the treatment of endocrinologic disorders with appropriate
hormones, the current pharmacologic approaches to Parkinsonism. There are
other examples, and everyone will have his favorite list. It is a long way, how-
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ever, from anything like a satisfactory state of affairs; the plain fact is that we
are not as good at this hiiglh teclhinology as the pulblic has been ledl to believe.
The point to be macle about this level of teclhnology is that it comes as tlle
restult of a geiLuine understanding of disease mneclhanisms, and whlen it becomes
available it is relatively inexpensive, relatively simple, and relatively easy to de-
liver. In most instainces, tlhe final, (lecisive remedly tturns out to be a new dIrug,
andl it seems to me likely that wve will continute to be dependent on the field of
plharmacology for the final advances against our major uinsolvedI (liseases, along
witlh vaccines agaiinst certaini infectious agents. The process of evolving new drtugs
anId( vaccinles is ain expensive one; it is the last stage of a long process of scientific
researclh that bJegins witlh the recognition of disease mechaniisms. However, tlle
wlhole process, incluLcdiing the cost of the final prodluct, will never be as hiiglh as
the present cost of medical car-e by the teclhnologies available todlay.
Offihand, I cannot tlhink of aniy important lhtuman disease for whichl medicine
possesses the capacity to prexvent or cure otutriglht where the cost of the teclhnology
is itself a major problem. The price is never as highl as the cost of managing the
same (liseasesdcur-iing the earlier stages.
It is whlen pllysicians ar-e iboggedI down by their incomplete teclhnologies, by
tlhe innumerable tlhings they are obliged to do in medicine when tlley lack a clear
tnd(lerstain(inlg of (lisease meclhanisms, that the (leficieincies of the lhealth-c-are
system are most coInspicuiouis. If I were a policy-maker, intereste(d in saving money
for lhealtlh care over the long lhatul, I ws%otuld regar(d it as ani act of hiiglh )rudence
to give highl priority to a lot mnore basic researclh in biologic science. Tllis is tlle
only way to get the ftull imileage that biology owses to thle science of me(licine,
even tlhoulghl it seems, as tise(I to l)e sai(i in the days whlein tlhe plhrase still lhad
somne meaning, like asking for the moon.
Ilhave been imi)lying, in theseremiar-ks, that most if not all of the major hutiman
dliseases represent approaclhable scientific problems, open to solLution sooner or
later. This lhas been my intentioin, for I believe it to be the simlple tr-utlh. I have
no mor-edifficulty in imagiining a lhtuman commtuinity free of disease tllanl I (1o in
envisioninglhealtlhy plants or hlealtlhy stocks of valuable ainimals. I (lo niot believe
in tlhe biological inevitalbility of dlisease. I see Ino reasoil to stuplpose tllat hleart
disease is anattural part of thelhtumain condlitioni, andl I am convinced that cancer
will eventually be entirely curable. I believe that we slhould be able to rid our-
selves of the disabling (liseases associated witlh aging, particularly stroke. Mly
point is tlhatwlen we are successftul in these ventures, the cost oflhealtlh care will
ten(d to go (lown ratlher than up.
There is one last matter to be dealt witlh,whOiclh inevitably arises wlhen medical
scientists talk the way I've been talking. Whlat will we all die of? WVithout otur
major diseases, will wejtist go on an(l on, with (lisastrouis effects on the popula-
tion problem? This seems to me a non-problem. WVe will continue to age, wear
out, and die; we will probably die according to the genetic sclhedules we have
inherited, some ofUs earlier, some later. I am not sure that otur total life spans
will be greatly increased by eliminating today's disease; some of us will live
longer, obviously, but probably not the majority. What is certain, however, is
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the qjuality of life will be measurably improved, and old age will be changed
from the foundlering dlisaster that it now represents for so many people into some-
thing more like a inatural human condition. It is worth the effort, it seems to me.
Indeed, I am not sure that we can afford, for the long run, any other course.
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